21 July 2022 - Pliant Therapeutics announced today that PLN-74809, its oral, dual-selective αvß6/αvß1 integrin inhibitor, has received fast track designation from the U.S. FDA for the potential treatment of primary sclerosing cholangitis. 

PLN-74809, the Company’s lead drug candidate, is currently being tested as part of the INTEGRIS-PSC Phase 2a clinical trial.

Read Pliant Therapeutics press release